Navigation path

Pharmaceuticals - Community Register


Community register of orphan medicinal products


Product information


EU orphan designation number: EU/3/12/1050   
Active ingredient: [2-Cyano-3-cyclopropyl-3-hydroxy-N-(3-methyl-4-trifluoromethylphenyl)prop-2-enamide]
Indication: Treatment of traumatic spinal cord injury
Sponsor: Algiax Pharmaceuticals GmbH
Max-Planck-Strasse 15a, D-40699 Erkrath, Deutschland

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
12/10/2012 Orphan designation EMA/OD/088/12 (2012)7227 of 10/10/2012